UNCOVERED: Zydus - Caught on Camera

Stocks in news: Vedanta, Kotak Mahindra Bank, Marico, Axis Bank, Trent and Zydus Lifesciences

Indian equity markets showed signs of recovery on Monday after softer-than-expected US jobs data was released. The Nifty 50 index ended the session up, suggesting improved investor confidence. Investors are watching key corporate updates from companies like Vedanta and Kotak Mahindra Bank for future trends. Firms reported various operational advancements…

The Economic Times · Oct 6

Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product…

The Economic Times · Aug 21

Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target

Shares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plunged thirty-six percent year-on-year for the first quarter, despite a nearly twenty-two percent increase in operational revenue. Expenses surged by over forty-one percent. However, the managing director…

The Economic Times · Aug 12

Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.

The Economic Times · Jun 17

Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?

Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's…

The Economic Times · May 20

Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition

Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business…

The Economic Times · May 14

Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors

Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. Zydus Lifesciences is nearing a US acquisition, while Maruti Suzuki commits to green logistics.

The Economic Times · May 14

Zydus gets USFDA approval for generic drug

The drug is used to treat high blood pressure in the lungs

The Hindu · Oct 1, 2022

Zydus starts supply of its needle-free 3-dose vaccine to govt

MUMBAI: Pharma major Zydus Cadila said on Wednesday it has started supplying its Covid-19 vaccine ZyCoV-D to the Centre, nearly six months after it had been authorised for emergency use in the 12 and above age group.

The Times of India · Feb 2, 2022

Zydus commences supply of COVID-19 vaccine ZyCoV-D to Central govt

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad.

Dynamite News · Feb 2, 2022